source
- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s e…Endpoints · 22d ago↗ source
- Updated: AstraZeneca sinks on unexpected heart drug trial failureAstraZeneca’s shares dropped in early trading Thursday after a heart disease treatment it is developing with Ionis Pharmaceuticals surprisingly failed in a late-stage trial. The companies had aimed…Endpoints · 22d ago↗ source
- Early Alert: Convenience Kit Issue from Medical Action IndustriesParticulates have the potential to be introduced into blood circulation and become lodged within blood vessels.fda medwatch